newsfilter
← Latest News
GlobeNewswire·

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for PRT7732, its first-in-class